Aileron Therapeutics announced that current President and COO, Brian Windsor, Ph.D., has been appointed President and CEO and will join the Board of Directors, effective March 11, 2024. Dr. Windsor succeeds Manuel Aivado, M.D., Ph.D., who has stepped down as CEO and will continue to serve on the Company’s Board of Directors. The transition follows the Company’s acquisition of Lung Therapeutics in October of last year.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALRN:
- Aileron Therapeutics: Board Shake-Up and Nasdaq Compliance Success
- Aileron Therapeutics’ Shareholders Approve Major Stock Proposals
- Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
- Aileron Therapeutics Grants COO Performance Bonus for 2023
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024